StockFacets
About
Sign-up
Sign-in
Earnings Calendar
Prices are updated after-hours
Published
Previous years
52
This month
1
This year
7
Publishing Date
2024 - 04 - 10
1
2024 - 03 - 11
1
2024 - 03 - 04
1
2024 - 02 - 26
1
2024 - 02 - 07
1
2024 - 01 - 29
1
2024 - 01 - 09
1
2023 - 12 - 11
1
2023 - 12 - 05
1
2023 - 11 - 28
1
2023 - 11 - 21
1
2023 - 10 - 25
1
2023 - 10 - 20
1
2023 - 09 - 27
1
2023 - 09 - 22
1
2023 - 09 - 07
1
2023 - 09 - 05
1
2023 - 08 - 14
1
2023 - 07 - 13
1
2023 - 07 - 06
1
2023 - 06 - 12
1
2023 - 06 - 05
1
2023 - 05 - 17
1
2023 - 05 - 15
1
2023 - 04 - 04
1
2023 - 03 - 15
1
2023 - 03 - 07
1
2023 - 02 - 23
1
2023 - 02 - 16
1
2023 - 02 - 15
1
2023 - 02 - 13
1
2023 - 02 - 02
1
2023 - 01 - 31
1
2023 - 01 - 27
1
2022 - 12 - 20
1
2022 - 12 - 16
1
2022 - 12 - 13
1
2022 - 11 - 22
1
2022 - 11 - 17
1
2022 - 11 - 11
1
2022 - 10 - 03
1
2022 - 09 - 20
1
2022 - 08 - 19
1
2022 - 07 - 20
1
2022 - 06 - 30
1
2022 - 05 - 12
1
2022 - 04 - 28
1
2022 - 03 - 03
1
2022 - 02 - 16
1
2022 - 02 - 01
1
2022 - 01 - 04
1
2021 - 12 - 15
1
Sector
Health technology
2
Transportation and warehousing
52
Tags
100
2
Acquisition
2
Africa
1
Agonist
2
Agreement
1
Alert
1
Antibody
1
Application
2
Approval
3
Arm
1
Authorization
1
Bioscience
52
Biotech-beach
12
Biotechnology
4
Clearance
1
Clinical-trials-phase-i
2
Clinical-trials-phase-ii
5
Conference
5
Day
2
Deal
1
Disease
1
Drug
5
Endocannabinoid
1
Events
6
Fda
2
Glaucoma
7
Global
2
Growth
1
Health
4
Hypertension
1
Innovation
1
Kidney
1
License
1
Life science
1
Market
1
Million
2
Money
4
N/a
10
Nasdaq
1
Obesity
2
Ocular
1
Ophthalmic emulsion
9
Payment
1
People
2
Pharma
1
Pharmaceutical
9
Phase 1
11
Phase 2
5
Phase 3
1
Positive
7
Positive results
1
Potential
2
Report
2
Research
4
Results
2
Review
5
Sbi-100
21
Study
8
Therapeutics
3
Trial
14
Entities
Nektar therapeutics
1
Sanofi
1
Skye bioscience, inc.
52
Symbols
AADI
53
ABBV
9
AKYA
15
ANIX
20
ANNX
10
APVO
28
ARTL
22
ASMB
24
BAX
7
CALA
11
CDAK
12
CHRS
41
COGT
18
CSTL
39
CTKB
10
DARE
90
DRUG
6
DTIL
34
ELAN
5
ENOB
9
ENSC
14
ENVB
28
EVFM
33
EVLO
33
FNCTF
7
GILD
10
HBIO
33
HRMY
31
IDXG
14
IDYA
21
IGMS
24
INVO
43
JNJ
16
LEXX
8
LLY
10
LMNL
14
MS
20
MSCLF
29
NBIX
18
PACB
22
PBIO
6
PCRX
25
PLSE
25
RCUS
8
REVB
6
RGC
13
RKDA
29
RNA
17
RXDX
13
SELB
25
SKYE
52
SLDB
22
SNY
18
SNYNF
16
SPRB
9
TWST
154
VIVO
38
XBIO
21
YTEN
61
ZIVO
9
Exchanges
Nasdaq
52
Crawled Date
2024 - 04 - 10
1
2024 - 03 - 11
1
2024 - 03 - 04
1
2024 - 02 - 26
1
2024 - 02 - 07
1
2024 - 01 - 29
1
2024 - 01 - 09
1
2023 - 12 - 11
1
2023 - 12 - 05
1
2023 - 11 - 28
1
2023 - 11 - 21
1
2023 - 10 - 25
1
2023 - 10 - 20
1
2023 - 09 - 27
1
2023 - 09 - 22
1
2023 - 09 - 07
1
2023 - 09 - 05
1
2023 - 08 - 14
1
2023 - 07 - 13
1
2023 - 07 - 06
1
2023 - 06 - 12
1
2023 - 06 - 05
1
2023 - 05 - 17
1
2023 - 05 - 15
1
2023 - 04 - 04
1
2023 - 03 - 15
1
2023 - 03 - 07
1
2023 - 02 - 23
1
2023 - 02 - 16
1
2023 - 02 - 15
1
2023 - 02 - 13
1
2023 - 02 - 02
1
2023 - 01 - 31
1
2023 - 01 - 27
1
2022 - 12 - 20
1
2022 - 12 - 16
1
2022 - 12 - 13
1
2022 - 11 - 22
1
2022 - 11 - 17
1
2022 - 11 - 11
1
2022 - 10 - 03
1
2022 - 09 - 20
1
2022 - 08 - 19
1
2022 - 07 - 20
1
2022 - 06 - 30
1
2022 - 05 - 12
1
2022 - 04 - 28
1
2022 - 03 - 03
1
2022 - 02 - 16
1
2022 - 02 - 01
1
2022 - 01 - 04
1
2021 - 12 - 15
1
Crawled Time
12:00
6
13:20
1
14:00
3
14:20
4
14:30
1
15:00
7
15:20
3
15:30
1
16:00
10
17:00
7
18:00
1
19:00
1
20:00
3
21:00
2
23:00
2
Source
www.biospace.com
46
www.globenewswire.com
6
Sort by:
after hours % change
|
delayed % change
|
gain open
|
gain high
|
gain close
|
publishing date
(GMT-12:00) International Date Line West
(GMT-11:00) American Samoa
(GMT-11:00) Midway Island
(GMT-10:00) Hawaii
(GMT-09:00) Alaska
(GMT-08:00) Pacific Time (US & Canada)
(GMT-08:00) Tijuana
(GMT-07:00) Arizona
(GMT-07:00) Chihuahua
(GMT-07:00) Mazatlan
(GMT-07:00) Mountain Time (US & Canada)
(GMT-06:00) Central America
(GMT-06:00) Central Time (US & Canada)
(GMT-06:00) Guadalajara
(GMT-06:00) Mexico City
(GMT-06:00) Monterrey
(GMT-06:00) Saskatchewan
(GMT-05:00) Bogota
(GMT-05:00) Eastern Time (US & Canada)
(GMT-05:00) Indiana (East)
(GMT-05:00) Lima
(GMT-05:00) Quito
(GMT-04:00) Atlantic Time (Canada)
(GMT-04:00) Caracas
(GMT-04:00) Georgetown
(GMT-04:00) La Paz
(GMT-04:00) Puerto Rico
(GMT-04:00) Santiago
(GMT-03:30) Newfoundland
(GMT-03:00) Brasilia
(GMT-03:00) Buenos Aires
(GMT-03:00) Greenland
(GMT-03:00) Montevideo
(GMT-02:00) Mid-Atlantic
(GMT-01:00) Azores
(GMT-01:00) Cape Verde Is.
(GMT+00:00) Casablanca
(GMT+00:00) Dublin
(GMT+00:00) Edinburgh
(GMT+00:00) Lisbon
(GMT+00:00) London
(GMT+00:00) Monrovia
(GMT+00:00) UTC
(GMT+01:00) Amsterdam
(GMT+01:00) Belgrade
(GMT+01:00) Berlin
(GMT+01:00) Bern
(GMT+01:00) Bratislava
(GMT+01:00) Brussels
(GMT+01:00) Budapest
(GMT+01:00) Copenhagen
(GMT+01:00) Ljubljana
(GMT+01:00) Madrid
(GMT+01:00) Paris
(GMT+01:00) Prague
(GMT+01:00) Rome
(GMT+01:00) Sarajevo
(GMT+01:00) Skopje
(GMT+01:00) Stockholm
(GMT+01:00) Vienna
(GMT+01:00) Warsaw
(GMT+01:00) West Central Africa
(GMT+01:00) Zagreb
(GMT+01:00) Zurich
(GMT+02:00) Athens
(GMT+02:00) Bucharest
(GMT+02:00) Cairo
(GMT+02:00) Harare
(GMT+02:00) Helsinki
(GMT+02:00) Jerusalem
(GMT+02:00) Kaliningrad
(GMT+02:00) Kyiv
(GMT+02:00) Pretoria
(GMT+02:00) Riga
(GMT+02:00) Sofia
(GMT+02:00) Tallinn
(GMT+02:00) Vilnius
(GMT+03:00) Baghdad
(GMT+03:00) Istanbul
(GMT+03:00) Kuwait
(GMT+03:00) Minsk
(GMT+03:00) Moscow
(GMT+03:00) Nairobi
(GMT+03:00) Riyadh
(GMT+03:00) St. Petersburg
(GMT+03:30) Tehran
(GMT+04:00) Abu Dhabi
(GMT+04:00) Baku
(GMT+04:00) Muscat
(GMT+04:00) Samara
(GMT+04:00) Tbilisi
(GMT+04:00) Volgograd
(GMT+04:00) Yerevan
(GMT+04:30) Kabul
(GMT+05:00) Ekaterinburg
(GMT+05:00) Islamabad
(GMT+05:00) Karachi
(GMT+05:00) Tashkent
(GMT+05:30) Chennai
(GMT+05:30) Kolkata
(GMT+05:30) Mumbai
(GMT+05:30) New Delhi
(GMT+05:30) Sri Jayawardenepura
(GMT+05:45) Kathmandu
(GMT+06:00) Almaty
(GMT+06:00) Astana
(GMT+06:00) Dhaka
(GMT+06:00) Urumqi
(GMT+06:30) Rangoon
(GMT+07:00) Bangkok
(GMT+07:00) Hanoi
(GMT+07:00) Jakarta
(GMT+07:00) Krasnoyarsk
(GMT+07:00) Novosibirsk
(GMT+08:00) Beijing
(GMT+08:00) Chongqing
(GMT+08:00) Hong Kong
(GMT+08:00) Irkutsk
(GMT+08:00) Kuala Lumpur
(GMT+08:00) Perth
(GMT+08:00) Singapore
(GMT+08:00) Taipei
(GMT+08:00) Ulaanbaatar
(GMT+09:00) Osaka
(GMT+09:00) Sapporo
(GMT+09:00) Seoul
(GMT+09:00) Tokyo
(GMT+09:00) Yakutsk
(GMT+09:30) Adelaide
(GMT+09:30) Darwin
(GMT+10:00) Brisbane
(GMT+10:00) Canberra
(GMT+10:00) Guam
(GMT+10:00) Hobart
(GMT+10:00) Melbourne
(GMT+10:00) Port Moresby
(GMT+10:00) Sydney
(GMT+10:00) Vladivostok
(GMT+11:00) Magadan
(GMT+11:00) New Caledonia
(GMT+11:00) Solomon Is.
(GMT+11:00) Srednekolymsk
(GMT+12:00) Auckland
(GMT+12:00) Fiji
(GMT+12:00) Kamchatka
(GMT+12:00) Marshall Is.
(GMT+12:00) Wellington
(GMT+12:45) Chatham Is.
(GMT+13:00) Nuku'alofa
(GMT+13:00) Samoa
(GMT+13:00) Tokelau Is.
tags :
Bioscience
symbols :
Skye
save search
Skye Bioscience Uplists to The Nasdaq Global Market
Published:
2024-04-10
(Crawled : 12:00)
- globenewswire.com
SKYE
|
$9.17
-20.98%
27K
|
Transportation and Warehousing
|
77.21%
|
O:
6.87%
H:
44.87%
C:
30.71%
nasdaq
bioscience
global
market
Skye Bioscience Announces $40 Million Private Placement Equity Financing
Published:
2024-03-11
(Crawled : 19:00)
- biospace.com/
SKYE
|
$9.17
-20.98%
27K
|
Transportation and Warehousing
|
21.95%
|
O:
-1.31%
H:
2.28%
C:
-23.95%
million
bioscience
Skye Bioscience Appoints Dr. Annalisa Jenkins to Board of Directors
Published:
2024-03-04
(Crawled : 12:00)
- globenewswire.com
SKYE
|
$9.17
-20.98%
27K
|
Transportation and Warehousing
|
-2.87%
|
O:
1.91%
H:
13.84%
C:
5.57%
bioscience
Skye Bioscience Completes Enrollment of Phase 2a Clinical Trial of SBI-100 Ophthalmic Emulsion in Glaucoma and Ocular Hypertension
Published:
2024-02-26
(Crawled : 12:00)
- globenewswire.com
SKYE
|
$9.17
-20.98%
27K
|
Transportation and Warehousing
|
125.69%
|
O:
6.66%
H:
7.43%
C:
6.72%
sbi-100
glaucoma
ocular
bioscience
hypertension
trial
Skye Bioscience to Present at Oppenheimer Investor Conference
Published:
2024-02-07
(Crawled : 21:00)
- biospace.com/
SKYE
|
$9.17
-20.98%
27K
|
Transportation and Warehousing
|
206.6%
|
O:
-0.94%
H:
4.57%
C:
-6.67%
conference
bioscience
Skye Bioscience Announces $50.25 Million Private Placement Equity Financing
Published:
2024-01-29
(Crawled : 23:00)
- biospace.com/
SKYE
|
$9.17
-20.98%
27K
|
Transportation and Warehousing
|
598.92%
|
O:
2.37%
H:
26.89%
C:
26.05%
million
bioscience
Skye Bioscience Receives IND Clearance for Phase 2 Clinical Trial of Nimacimab in Obesity and Chronic Kidney Disease
Published:
2024-01-09
(Crawled : 16:00)
- biospace.com/
SKYE
|
$9.17
-20.98%
27K
|
Transportation and Warehousing
|
571.49%
|
O:
-7.02%
H:
29.11%
C:
15.56%
SNY
|
News
|
$46.125
0.71%
0.7%
3.7M
|
Health Technology
|
-10.98%
|
O:
0.74%
H:
0.0%
C:
0.0%
obesity
disease
kidney
bioscience
clearance
trial
Skye Bioscience Responds to OTC Markets Promotional Policy
Published:
2023-12-11
(Crawled : 16:00)
- biospace.com/
SKYE
|
$9.17
-20.98%
27K
|
Transportation and Warehousing
|
364.29%
|
O:
10.0%
H:
15.58%
C:
3.9%
bioscience
Skye Bioscience and Tautomer Bioscience Enter Exclusive License for SBI-100 for Development and Sale of Products for Chronic Pain and Other Indications in South Africa and Rest of Africa
Published:
2023-12-05
(Crawled : 17:00)
- biospace.com/
SKYE
|
$9.17
-20.98%
27K
|
Transportation and Warehousing
|
812.92%
|
O:
37.64%
H:
21.63%
C:
15.92%
sbi-100
license
bioscience
africa
Skye Bioscience Treats First Patient in Glaucoma Phase 2 Study of SBI-100 Ophthalmic Emulsion
Published:
2023-11-28
(Crawled : 12:00)
- globenewswire.com
SKYE
|
$9.17
-20.98%
27K
|
Transportation and Warehousing
|
948.39%
|
O:
3.23%
H:
6.25%
C:
-3.13%
sbi-100
glaucoma
bioscience
study
phase 2
Skye Bioscience to Present at BTIG Ophthalmology Day and OIS XIII Ophthalmology Innovation Summit
Published:
2023-11-21
(Crawled : 14:30)
- biospace.com/
SKYE
|
$9.17
-20.98%
27K
|
Transportation and Warehousing
|
860.12%
|
O:
1.03%
H:
0.0%
C:
-5.85%
day
innovation
bioscience
Skye Bioscience Announces Positive Phase 1 Trial Results for SBI-100 Ophthalmic Emulsion, Its First-in-Class CB1 Agonist Being Developed for the Treatment of Glaucoma
Published:
2023-10-25
(Crawled : 14:00)
- biospace.com/
SKYE
|
$9.17
-20.98%
27K
|
Transportation and Warehousing
|
574.27%
|
O:
-0.31%
H:
0.0%
C:
-23.0%
sbi-100
glaucoma
agonist
positive
bioscience
treatment
trial
results
Skye Bioscience to Host Virtual Investor Day on October 25, 2023: "CB1 Axis: Unlocking the Pharmaceutical Potential of the Endocannabinoid System"
Published:
2023-10-20
(Crawled : 21:00)
- biospace.com/
SKYE
|
$9.17
-20.98%
27K
|
Transportation and Warehousing
|
524.04%
|
O:
-2.07%
H:
1.96%
C:
1.96%
day
bioscience
endocannabinoid
potential
Skye Bioscience Receives Clinical Site Approvals for Glaucoma Phase 2a Trial
Published:
2023-09-27
(Crawled : 15:30)
- biospace.com/
SKYE
|
$9.17
-20.98%
27K
|
Transportation and Warehousing
|
Email alert
Add to watchlist
glaucoma
bioscience
trial
Skye Bioscience Announces Participation at Upcoming Investor Conferences
Published:
2023-09-22
(Crawled : 20:00)
- biospace.com/
SKYE
|
$9.17
-20.98%
27K
|
Transportation and Warehousing
|
Email alert
Add to watchlist
bioscience
Skye Bioscience Reverse Stock Split to Be Effective on September 8th
Published:
2023-09-07
(Crawled : 23:00)
- biospace.com/
SKYE
|
$9.17
-20.98%
27K
|
Transportation and Warehousing
|
104738.71%
|
O:
-3.23%
H:
16.67%
C:
16.67%
bioscience
Skye Bioscience to Present at H.C. Wainwright 25th Annual Global Investment Conference
Published:
2023-09-05
(Crawled : 17:00)
- biospace.com/
SKYE
|
$9.17
-20.98%
27K
|
Transportation and Warehousing
|
95488.24%
|
O:
-10.0%
H:
11.11%
C:
7.84%
conference
bioscience
global
Skye Bioscience to Present at H.C. Wainwright 3rd Annual Ophthalmology Virtual Conference
Published:
2023-08-14
(Crawled : 17:00)
- biospace.com/
SKYE
|
$9.17
-20.98%
27K
|
Transportation and Warehousing
|
98384.85%
|
O:
0.0%
H:
3.03%
C:
-3.64%
conference
bioscience
Skye Bioscience Receives Positive Safety Review for Final Cohort of Fully-Enrolled Phase 1 Study of SBI-100 Ophthalmic Emulsion
Published:
2023-07-13
(Crawled : 16:00)
- biospace.com/
SKYE
|
$9.17
-20.98%
27K
|
Transportation and Warehousing
|
76191.08%
|
O:
-6.1%
H:
6.5%
C:
4.5%
sbi-100
review
positive
bioscience
study
Skye Bioscience Completes Production and Filling of Investigational Drug Material in Preparation for Phase 2a Glaucoma Clinical Trial
Published:
2023-07-06
(Crawled : 16:00)
- biospace.com/
SKYE
|
$9.17
-20.98%
27K
|
Transportation and Warehousing
|
72769.96%
|
O:
-9.87%
H:
19.4%
C:
19.4%
glaucoma
drug
bioscience
trial
← Previous
1
2
3
Next →
Gainers vs Losers
56%
44%
Top 10 Gainers
INVO
|
$1.76
131.58%
56.82%
230M
|
Health Technology
SINT
|
$0.0365
59.39%
37.26%
470M
|
Health Technology
WISA
4
|
$9.19
50.66%
33.7%
65M
|
Electronic Technology
EDBL
|
News
|
$6.73
47.91%
32.39%
13M
|
GCTK
|
$0.715
36.27%
26.62%
640K
|
Manufacturing
TCON
|
$2.33
36.26%
26.61%
2M
|
Health Technology
TIRX
|
$0.48
6.43%
24.58%
4.8M
|
KZIA
|
$0.38
30.58%
23.42%
300K
|
Health Technology
VNDA
|
News
|
$5.23
29.14%
22.56%
24M
|
Health Technology
ATNF
|
$1.91
29.05%
22.51%
310K
|
Your saved searches
Save your searches and get alerts when important news are released.